Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;61(3):301-308.

Recent and current clinical trials in canine appendicular osteosarcoma

Andrew C Poon  1 , Arata Matsuyama  1 , Anthony J Mutsaers  1
Affiliations
Review

Recent and current clinical trials in canine appendicular osteosarcoma

Andrew C Poon et al. Can Vet J. 2020 Mar.

Abstract
in English, French

Osteosarcoma (OSA) is an aggressive primary bone tumor in the domestic dog that most often occurs within the appendicular skeleton. Despite the use of adjuvant chemotherapy, most dogs succumb to metastatic disease within 1 year of diagnosis. To improve this outcome, substantial research is currently focused on investigating novel therapies. Herein, we review emerging treatments and clinical trials that, if proven efficacious, could revolutionize the standard of care for canine appendicular OSA. This article includes a critical perspective on the safety, efficacy, and limitations of select immunotherapy, virotherapy, radiotherapy, targeted therapy, and personalized medicine trials, all of which reflect similar investigations taking place in human oncology. These clinical trials represent a major evolution in the overall approach to therapy for dogs with appendicular OSA that could have significant implications for improving survival.

Essais cliniques récents et en cours sur l’ostéosarcome appendiculaire canin. L’ostéosarcome (OSA) est une tumeur osseuse primaire agressive chez le chien domestique qui se produit fréquemment dans le squelette appendiculaire. Malgré l’utilisation de chimiothérapie complémentaire, la majorité des chiens succombent aux métastases en dedans d’une année du diagnostic. Afin d’améliorer ce résultat, de la recherche substantielle est actuellement concentrée sur l’étude de thérapies nouvelles. À cet égard, nous révisons les traitements émergents et les essais cliniques qui, s’ils s’avèrent efficaces, pourraient révolutionner le standard de soins pour les OSA appendiculaires canins. Le présent article inclus une perspective critique de la sécurité, l’efficacité et les limitations d’un choix d’immunothérapie, de virothérapie, de radiothérapie, de thérapies ciblées et d’essais médicaux personnalisés, qui reflètent tous des investigations similaires effectuées en oncologie humaine. Ces essais cliniques représentent une évolution majeure dans l’approche globale à la thérapie de chiens avec OSA appendiculaire qui pourrait avoir des implications significatives pour améliorer la survie.(Traduit par Dr Serge Messier).

PubMed Disclaimer

References

    1. Egenvall A, Nødtvedt A, von Euler H. Bone tumors in a population of 400 000 insured Swedish dogs up to 10 y of age: Incidence and survival. Can J Vet Res. 2007;71:292–299. - PMC - PubMed
    1. Wolke RE, Nielsen SW. Site incidence of canine osteosarcoma. J Small Anim Pract. 1966;7:489–492. - PubMed
    1. Anfinsen KP, Grotmol T, Bruland OS, Jonasdottir TJ. Breed-specific incidence rates of canine primary bone tumors — A population based survey of dogs in Norway. Can J Vet Res. 2011;75:209–215. - PMC - PubMed
    1. Rubin JA, Suran JN, Brown DC, Agnello KA. Factors associated with pathological fractures in dogs with appendicular primary bone neoplasia: 84 cases (2007–2013) J Am Vet Med Assoc. 2015;247:917–923. - PubMed
    1. Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014;28:554–563. - PMC - PubMed

LinkOut - more resources